Washington, DC: The United States Drug Enforcement Administration (DEA) has rejected a pair of administrative rescheduling petitions challenging the federal classification of cannabis as a Schedule I controlled substance with no accepted medical utility. The decision continues to classify marijuana in the same category as heroin.
However, in a separate announcement, the agency said that it is adopting policy changes designed to expand the production of research-grade cannabis for FDA-approved clinical protocols.
Presently, any clinical trial involving cannabis must access source material cultivated at the University of Mississippi – an arbitrary prohibition that is not in place for other controlled substances.
Today, the agency announced for the first time that it will consider applications from multiple parties, including private entities, to produce marijuana for FDA-approved research protocols as well as for “commercial product development.” Ironically, this change was initially recommended by the DEA’s own administrative law judge in 2007, but that decision was ultimately rejected by the agency in 2011.
Commenting on the DEA’s actions, NORML Deputy Director Paul Armentano said: “While this announcement is a significant step toward better facilitating and expanding clinical investigations into cannabis’ therapeutic efficacy, ample scientific evidence already exists to remove cannabis from its schedule I classification and to acknowledge its relative safety compared to other scheduled substances, like opioids, and unscheduled substances, such as alcohol. Ultimately, the federal government ought to remove cannabis from the Controlled Substances Act altogether in a manner similar to alcohol and tobacco, thus providing states the power to establish their own marijuana regulatory policies free from federal intrusion.”
He added: “Since the DEA has failed to take such action, then it is incumbent that members of Congress act swiftly to amend cannabis’ criminal status in a way that comports with both public and scientific opinion. Failure to do so continues the federal government’s ‘Flat Earth’ position. It willfully ignores the well-established therapeutic properties associated with the plant and it ignores the laws in 26 states recognizing marijuana’s therapeutic efficacy.”
A recent review of FDA-approved clinical studies evaluating the safety and efficacy of herbal cannabis concluded: “Based on evidence currently available the Schedule I classification is not tenable; it is not accurate that cannabis has no medical value, or that Information on safety is lacking.”
Added Armentano: “The DEA’s decision is strictly a political one. There is nothing scientific about willful ignorance.”
The DEA has previously rejected several other rescheduling petitions, including a 2002 petition filed by a coalition of marijuana law reform and health advocacy organizations, and a 1972 petition filed by NORML. The petitions that triggered this latest DEA action were filed in 2009 by a nurse practitioner and in 2011 by then-Govs. Christine Gregoire of Washington and Lincoln Chafee of Rhode Island.
For more information, please contact Paul Armentano, NORML Deputy Director.